Offer - Urjas Oil for just Rs 1 X
Tafmune EM is an allopathic medicine Secondary and off-label uses of Tafmune EM have also been mentioned below. The correct dosage of Tafmune EM depends on the patient's age, gender, and medical history. This information has been provided in detail in the dosage section.
Tafmune EM is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
13 - 18 years (Adolescent) |
|
2 - 12 years (Child) |
|
Adult |
|
Geriatric |
|
Is the use of Tafmune EM safe for pregnant women?
There are no side effects of Tafmune EM in pregnant women.
Is the use of Tafmune EM safe during breastfeeding?
Tafmune EM may have very limited harmful effects for breastfeeding women.
What is the effect of Tafmune EM on the Kidneys?
Tafmune EM may have mild side effects on the kidneys.
What is the effect of Tafmune EM on the Liver?
Tafmune EM is rarely harmful for the liver.
What is the effect of Tafmune EM on the Heart?
Side effects of Tafmune EM rarely affect the heart.
Tafmune EM should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Tafmune EM unless your doctor advises you to do so -
Is this Tafmune EM habit forming or addictive?
Forming a habit of Tafmune EM has not been reported.
Interaction between Food and Tafmune EM
Taking Tafmune EM with food is safe.
Interaction between Alcohol and Tafmune EM
Consult your doctor before consuming alcohol while taking Tafmune EM as it can have severe side effects.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Emtriva®(emtricitabine)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1179
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 803-804
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Viread® (tenofovir disoproxil fumarate)